Brian Piekos

Chief Financial Officer

Gemini Therapeutics, Inc. /DE Gemini Therapeutics, Inc. /DE KalVista Pharmaceuticals, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 1 saleMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€60k

▼ Sales (1 ops.)

€32k

Latest filing published 20 Apr 2026 for KalVista Pharmaceuticals, Inc.. Read the official filing

Filing timeline

BuySale

Brian Piekos

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Brian Piekos: trading record in brief

Brian Piekos, listed as finance chief, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in KalVista Pharmaceuticals, Inc., Disc Medicine, Inc. and AMAG Pharmaceuticals Inc. Over a trading history stretching from 16 November 2020 to 17 April 2026, the count stands at 7 filings.

Market trades split into 1 purchase (€60k) and 1 sale (€32k). Purchases outweigh sales by €28k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant and 3 option exercises. 2026 to date brings no purchases and 1 sale.

On 20 April 2026 came the latest disclosure, an open-market sale for €32k in KalVista Pharmaceuticals, Inc. The last purchase on record was published on 18 May 2021, which is 1,982 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.